Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on January 9, 2026. The filing addresses a corporate action regarding the Company's At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally dated May 20, 2024.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figures disclosed relate to the equity offering program:
- Remaining Offering Capacity: Up to $7,379,813 in aggregate gross sales price.
- Shares Sold to Date: Approximately $6,165,114 in aggregate gross sales price.
- Stock Details: Common Stock, par value $0.0001 per share, trading symbol GRI on the Nasdaq Capital Market.
Material Changes
The material change reported is the filing of a prospectus supplement to increase the maximum number of shares issuable under the existing Sales Agreement. Additionally, the Company noted that certain provisions of a Securities Purchase Agreement dated December 11, 2025, have been waived to permit issuances under the Sales Agreement.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the context of the equity issuance. The Company is identified as an Emerging Growth Company. The legality of the share issuance was confirmed by an opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Investor Verification Checklist
- Verify the total number of shares authorized under the updated prospectus supplement.
- Confirm the specific provisions waived in the December 11, 2025, Securities Purchase Agreement.
- Review the latest 10-K or 10-Q filings for current liquidity, cash burn rate, and overall debt position, as this 8-K does not provide them.
- Check the current market price of GRI stock to assess the dilution impact of the remaining $7.38 million offering capacity.